Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 …,

Safety and biomarker goals were met in both studies, supporting plans to advance BIIB122/DNL151 into late-stage clinical development in Parkinson’s …, Safety and biomarker goals were met in both studies, supporting plans to advance BIIB122/DNL151 into late-stage clinical development in Parkinson’s …, Read More

Scroll to Top